CanSino Biologics Inc (CJH) - Total Assets
Based on the latest financial reports, CanSino Biologics Inc (CJH) holds total assets worth €7.18 Billion EUR (≈ $8.39 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check CanSino Biologics Inc (CJH) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CanSino Biologics Inc - Total Assets Trend (2016–2025)
This chart illustrates how CanSino Biologics Inc's total assets have evolved over time, based on quarterly financial data. Check CJH operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CanSino Biologics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
CanSino Biologics Inc's total assets of €7.18 Billion consist of 53.5% current assets and 46.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 17.0% |
| Accounts Receivable | €782.88 Million | 10.9% |
| Inventory | €338.31 Million | 4.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €313.69 Million | 4.4% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how CanSino Biologics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CanSino Biologics Inc (CJH) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CanSino Biologics Inc's current assets represent 53.5% of total assets in 2025, an increase from 45.0% in 2016.
- Cash Position: Cash and equivalents constituted 17.0% of total assets in 2025, up from 16.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 6.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 10.9% of total assets.
CanSino Biologics Inc Competitors by Total Assets
Key competitors of CanSino Biologics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
CanSino Biologics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.55 | 2.00 | 13.24 |
| Quick Ratio | 3.23 | 1.86 | 12.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €2.76 Billion | €2.59 Billion | €5.01 Billion |
CanSino Biologics Inc - Advanced Valuation Insights
This section examines the relationship between CanSino Biologics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.21 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -9.8% |
| Total Assets | €7.18 Billion |
| Market Capitalization | $375.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values CanSino Biologics Inc's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: CanSino Biologics Inc's assets decreased by 9.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for CanSino Biologics Inc (2016–2025)
The table below shows the annual total assets of CanSino Biologics Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €7.18 Billion ≈ $8.39 Billion |
-9.81% |
| 2024-12-31 | €7.96 Billion ≈ $9.30 Billion |
-14.60% |
| 2023-12-31 | €9.32 Billion ≈ $10.89 Billion |
-18.75% |
| 2022-12-31 | €11.47 Billion ≈ $13.41 Billion |
-3.41% |
| 2021-12-31 | €11.87 Billion ≈ $13.88 Billion |
+75.96% |
| 2020-12-31 | €6.75 Billion ≈ $7.89 Billion |
+278.15% |
| 2019-12-31 | €1.78 Billion ≈ $2.09 Billion |
+124.22% |
| 2018-12-31 | €795.88 Million ≈ $930.46 Million |
-8.14% |
| 2017-12-31 | €866.36 Million ≈ $1.01 Billion |
+165.61% |
| 2016-12-31 | €326.17 Million ≈ $381.33 Million |
-- |
About CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are i… Read more